Literature DB >> 26917533

[Bioinformatics analysis on molecular mechanism of ribavirin and interferon-α in treating MERS-CoV].

Y Zheng1, Q Y Wang.   

Abstract

OBJECTIVE: To study the molecular mechanism of ribavirin and interferon-α in the treatment of Middle East Respiratory Syndrome (MERS) by bio-informatic methods.
METHODS: MERS-CoV-related microarray data was searched from Array Express database and analyzed by Agilent GeneSpring GX software. Target genes of ribavirin and interferon-α were acquired from Comparative Toxicogenomics Database (CTD). PANTHER TOOL and DAVID platform were used for the analysis of GO and Pathway.
RESULTS: One set of MERS-CoV related microarray data and 27 target genes of ribavirin and interferon-α were acquired from the online databases. Data on Genes from microarray were divided into two time-related gene clusters by using the Unsupervised Hierarchical Clustering. Data from the GO analysis indicated that the target genes of ribavirin and interferon-α as well as the genes from the microarray were mainly enriched in 10 biological processes, including cellular process, metabolic process, immune system process and biological regulation, et al. Data on drug target genes, first and second cluster of microarray would involve 9, 3 and 23 signaling pathways respectively, and only the former two showed 7 common pathways, which were related to pathogen recognition, cytokine release and autoimmune response.
CONCLUSION: Ribavirin in combination with interferon-α might have therapeutic effects on MERS patients through several signaling pathways. Genes in the second cluster might serve as target genes to be used for screening of new drugs in treating the MERS-CoV infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26917533     DOI: 10.3760/cma.j.issn.0254-6450.2016.02.028

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  9 in total

1.  Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.

Authors:  George D Liatsos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 2.  MERS coronavirus outbreak: Implications for emerging viral infections.

Authors:  Awad Al-Omari; Ali A Rabaan; Samer Salih; Jaffar A Al-Tawfiq; Ziad A Memish
Journal:  Diagn Microbiol Infect Dis       Date:  2018-10-18       Impact factor: 2.803

Review 3.  A review of treatment modalities for Middle East Respiratory Syndrome.

Authors:  Yin Mo; Dale Fisher
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

4.  Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.

Authors:  Eduardo Huarte; Roddy S O'Connor; Michael T Peel; Selene Nunez-Cruz; John Leferovich; Ashish Juvekar; Yan-Ou Yang; Lisa Truong; Taisheng Huang; Ahmad Naim; Michael C Milone; Paul A Smith
Journal:  Clin Cancer Res       Date:  2020-09-30       Impact factor: 12.531

5.  Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.

Authors:  Chi Zhang; Zhao Wu; Jia-Wen Li; Hong Zhao; Gui-Qiang Wang
Journal:  Int J Antimicrob Agents       Date:  2020-03-29       Impact factor: 5.283

Review 6.  Current evidence for directed and supportive investigational therapies against COVID-19.

Authors:  R van Rensburg; V Pillay-Fuentes Lorente; E H Decloedt
Journal:  Afr J Thorac Crit Care Med       Date:  2020-04-30

Review 7.  A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.

Authors:  Ali A Rabaan; Shamsah H Alahmed; Ali M Bazzi; Hatem M Alhani
Journal:  J Med Microbiol       Date:  2017-08-31       Impact factor: 2.472

Review 8.  A global treatments for coronaviruses including COVID-19.

Authors:  Bahman Yousefi; Saeid Valizadeh; Hadi Ghaffari; Azadeh Vahedi; Mohsen Karbalaei; Majid Eslami
Journal:  J Cell Physiol       Date:  2020-05-11       Impact factor: 6.513

Review 9.  Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.

Authors:  Abubakar Umar Anka; Mohammed Ibrahim Tahir; Sharafudeen Dahiru Abubakar; Mohamed Alsabbagh; Zeineb Zian; Haleh Hamedifar; Araz Sabzevari; Gholamreza Azizi
Journal:  Scand J Immunol       Date:  2020-12-03       Impact factor: 3.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.